ANGLE plc

6 Followers

ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE plc’s lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalised cancer care. ANGLE plc has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe.

parsortix cancer circulating tumor cells diagnostic cell seaparation angle plc tumor andrew newland ctc novocellus geomerics cancer diagnostics

Activity
About

Liquid biopsy from a simple blood test enabling personalised cancer care | Shares Investor Evening Manchester | 31 March 2015

8 years ago • 1210 Views

ANGLE plc

Presentations

Angle interim results 2012 26jan12

Angle parsortix presentation 07oct11

ANGLE Preliminary Results 2012 26jul12

ANGLE Interim Results 2013 31jan13

ANGLE Peliminary Results 2013 31jul13

ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013

ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum

Liquid biopsy from a simple blood test enabling personalised cancer care | Shares Investor Evening Manchester | 31 March 2015

Parsortix non-invasive cancer diagnostics | 3 September 2014

The Stock Market Show | 13 September 2014

Shares Investor Evening 29 October 2014

Personalised Cancer Care December 2014

Liquid Biopsy 29 January 2015

ANGLE shares investor evening 15 April 2015

Presentation 2 July 2015: Proactive Investors Forum

Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015

Documents

ANGLE Annual Report 2013

About the Parsortix System